Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response

Cliona Grant, MD, Sattva S. Neelapu, MD, Larry W Kwak, MD, PhD, Kieron Dunleavy, MD, Therese White, RN, Barry W. Miller, MS, Elaine S. Jaffe, MD, Seth M. Steinberg, PhD, Brian Healey Bird, MB, MRCP, Wyndham H. Wilson, MD, PhD

Blood (2011) 118 (21): 2707.

https://doi.org/10.1182/blood.V118.21.2707.2707

Published: 2011

Journal Articles

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

Blood (2011) 117 (2): 563–574.

https://doi.org/10.1182/blood-2010-05-284984

Published: 2011

Includes: Supplemental data

Journal Articles

NRF2 at the Interface of Oxidative and Endoplasmic Reticulum Stress Pathways Is a Critical Integrator of Bortezomib Response in Mantle Cell Lymphoma in Vitro and In Vivo .

Marc A Weniger, PhD, Edgar Gil Rizzatti, MD, PhD, Patricia Perez Galan, PhD, Delong Liu, PhD, Peter J Munson, PhD, Nalini Raghavachari, PhD, Therese White, Megan M Disinski, Wyndham H Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 727.

https://doi.org/10.1182/blood.V114.22.727.727

Published: 2009

Journal Articles

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Ndegwa Njuguna, MD, Paul V Beum, PhD, Berengere Vire, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Wyndham H. Wilson, MD, PhD, Ronald P Taylor, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 4208.

https://doi.org/10.1182/blood.V112.11.4208.4208

Published: 2008

Journal Articles

The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways

Yair Herishanu, MD, Berengere Vire, PhD, Delong Liu, PhD, Federica Gibellini, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Ndegwa Njuguna, MD, Nalini Raghavachari, PhD, Poching Liu, PhD, Stefania Pittaluga, MD, PhD, Peter J Munson, PhD, Wyndham H. Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 356.

https://doi.org/10.1182/blood.V112.11.356.356

Published: 2008

Journal Articles

Molecular Effects of Rituximab on CLL Cells In Vivo : Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression.

Adrian Wiestner, MD, PhD, Elinor Lee, BA, Berengere Vire, PhD, Federica Gibellini, PhD, Ndegwa Njuguna, MD, Yair Herishanu, MD, Delong Liu, PhD, Peter Munson, PhD, Nalini Raghavachari, PhD, Therese White, RN, Gerald E. Marti, MD, PhD, Wyndham H. Wilson, MD, PhD

Blood (2007) 110 (11): 2048.

https://doi.org/10.1182/blood.V110.11.2048.2048

Published: 2007

Journal Articles

ZAP-70 Expression Is Associated with Increased Migration to SDF-1 in Chronic Lymphocytic Leukemia.

Yuji Miura, MD, PhD, Elinor Lee, BA, Federica Gibellini, PhD, Therese White, RN, Gerald Marti, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 587.

https://doi.org/10.1182/blood.V108.11.587.587

Published: 2006

Journal Articles

Rituximab Induces an Interferon Gene Expression Signature in Patients with CLL.

Elinor Lee, BA, Xiuli Xu, PhD, Peter Munson, PhD, Ronald Cooper, BA, Nalini Raghavachari, PhD, Therese White, RN, Gerald E. Marti, MD,PhD, Wyndham H. Wilson, MD,PhD, Adrian Wiestner, MD,PhD

Blood (2006) 108 (11): 4988.

https://doi.org/10.1182/blood.V108.11.4988.4988

Published: 2006

Journal Articles

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Raymond Lai, MD/PhD, Masanori Daibata, MD, Therese White, RN, Kieron Dunleavy, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 830.

https://doi.org/10.1182/blood.V108.11.830.830

Published: 2006

Journal Articles

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Adrian Wiestner, MD, PhD, Kieron Dunleavy, MD, Edgar G. Rizzatti, MD/PhD, Hui Liu, Msc, Gerald E. Marti, MD, Therese White, RN, Wyndham Wilson, MD/PhD

Blood (2005) 106 (11): 4744.

https://doi.org/10.1182/blood.V106.11.4744.4744

Published: 2005

Journal Articles

Differential Gene Expression in CLL Cells from Bone Marrow and Peripheral Blood Suggests a Role of Bone Marrow Stroma in Leukemic Cell Proliferation.

Adrian Wiestner, MD, PhD, Gerald E. Marti, MD, Eric M. Billings, PhD, Hui Liu, Msc, Elinor Lee, BA, Therese White, RN, Wyndham H. Wilson, MD/PhD

Blood (2005) 106 (11): 708.

https://doi.org/10.1182/blood.V106.11.708.708

Published: 2005

Journal Articles

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

Kieron Dunleavy, Frances Hakim, Hyun Kyung Kim, John E. Janik, Nicole Grant, Takayuki Nakayama, Therese White, George Wright, Larry Kwak, Ronald Gress, Giovanna Tosato, Wyndham H. Wilson

Blood (2005) 106 (3): 795–802.

https://doi.org/10.1182/blood-2004-08-3198

Published: 2005

Journal Articles

Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.

Kieron Dunleavy, M.D., John Janik, M.D., Juan Gea-Banacloche, M.D., Margaret Shovlin, B.S.N., Therese White, M.S.N., Neta Goldschmidt, M.D., Nicole Grant, M.P.H., Omer Koc, M.D., Stefania Pittaluga, M.D., Elaine Jaffe, M.D., Louis Staudt, M.D., Ph.D., Wyndham H. Wilson, M.D., Ph.D.

Blood (2004) 104 (11): 1385.

https://doi.org/10.1182/blood.V104.11.1385.1385

Published: 2004

Journal Articles

Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia

Upendra P. Hegde, Wyndham H. Wilson, Therese White, Bruce D. Cheson

Blood (2002) 100 (6): 2260–2262.

https://doi.org/10.1182/blood.V100.6.2260

Published: 2002

NARROW

Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

NRF2 at the Interface of Oxidative and Endoplasmic Reticulum Stress Pathways Is a Critical Integrator of Bortezomib Response in Mantle Cell Lymphoma in Vitro and In Vivo .

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways

Molecular Effects of Rituximab on CLL Cells In Vivo : Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression.

ZAP-70 Expression Is Associated with Increased Migration to SDF-1 in Chronic Lymphocytic Leukemia.

Rituximab Induces an Interferon Gene Expression Signature in Patients with CLL.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Differential Gene Expression in CLL Cells from Bone Marrow and Peripheral Blood Suggests a Role of Bone Marrow Stroma in Leukemic Cell Proliferation.

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.

Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only